Yvonne Diaz, Co-Founder of Oncogene Cancer Research and Director of Global Media Relations and Social Media at EY, shared on X:
“Dr Mal Itchins highlights 19 yrs of progress in ROS1 w latest data on zidesamtinib at WCLC26.
Congratulates work by RO1ders jfreemandaily Lilian Leigh ProjectBreath. ’12 yrs ago we didn’t test for ROS1 in Australia but thanks to a clinical trial Lillian is still here today.”
You might be interested in:
WCLC 2026 Opens in Seoul: Targeted Therapy Moves Earlier as SCLC Enters a New Therapeutic Era
Other articles featuring Yvonne Diaz on OncoDaily.
